Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
Granolleras
C
C
Department of Nephrology, University Hospital, Nîmes, France.
Branger
B
B
Deschodt
G
G
Shaldon
S
S
Nonnast-Daniel
B
B
Pollok
M
M
D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000906:Antibodies / Q000032:analysis; D004921:Erythropoietin / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D012646:Self Administration
D000906:Antibodies; D011994:Recombinant Proteins; D004921:Erythropoietin